State Board of Administration of Florida Retirement System grew its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 108,708 shares of the biopharmaceutical company’s stock after acquiring an additional 2,200 shares during the period. State Board of Administration of Florida Retirement System owned 0.13% of Alnylam Pharmaceuticals worth $8,671,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in ALNY. First Manhattan Co. bought a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth approximately $135,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Alnylam Pharmaceuticals during the first quarter valued at approximately $148,000. Westpac Banking Corp acquired a new position in Alnylam Pharmaceuticals during the first quarter valued at approximately $202,000. Prudential Financial Inc. acquired a new position in Alnylam Pharmaceuticals during the first quarter valued at approximately $215,000. Finally, CIBC Asset Management Inc acquired a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $221,000. 94.27% of the stock is owned by institutional investors.
Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) opened at 76.21 on Friday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $31.38 and a 12 month high of $89.45. The stock has a 50 day moving average of $81.55 and a 200 day moving average of $68.51. The company’s market capitalization is $6.99 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The company had revenue of $15.93 million for the quarter, compared to the consensus estimate of $23.86 million. During the same quarter in the prior year, the company earned ($1.05) earnings per share. The company’s quarterly revenue was up 82.9% on a year-over-year basis. Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post ($5.18) EPS for the current fiscal year.
A number of research analysts recently issued reports on ALNY shares. Chardan Capital set a $110.00 price objective on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Monday, June 12th. Needham & Company LLC boosted their price objective on shares of Alnylam Pharmaceuticals from $68.00 to $98.00 and gave the company a “buy” rating in a report on Tuesday, June 27th. Jefferies Group LLC reiterated a “buy” rating and issued a $102.00 price target on shares of Alnylam Pharmaceuticals in a report on Thursday, June 22nd. BidaskClub cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 29th. Finally, Piper Jaffray Companies set a $116.00 price target on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, May 24th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $81.11.
Alnylam Pharmaceuticals Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.